Terizidone
Based on 1 Customer Validation
Terizidone is an antibacterial agent. Terizidone acts as a prodrug to release D-cycloserine (HY-B0030), which competitively inhibits alanine racemase and D-alanine:D-alanine ligase, interfering with peptidoglycan synthesis and thereby inhibiting cell wall assembly in Mycobacterium tuberculosis. Terizidone does not significantly inhibit human liver microsomal CYP1A2 or CYP2C9 enzyme activity. Terizidone can be used in research related to tuberculosis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.05%
- CAS. Nr.: 25683-71-0
- Formel: C14H14N4O4
- Molecular Weight:302.29
-
Speicherung:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
In Vitro
Terizidone is a prodrug obtained by condensation of two molecules of cycloserine with one molecule of terephthalaldehyde; the active component D-cycloserine (HY-B0030) is a D-alanine analog that competitively inhibits alanine racemase and D-alanine:D-alanine ligase[1].
Terizidone does not inhibit CYP1A2-dependent Phenacetin (HY-B0476) O-deethylation or CYP2C9-dependent Diclofenac (HY-15036) 4'-hydroxylation in human liver microsomes[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 25683-71-0
-
Appearance Solid
-
Molecular Weight 302.29
-
Formel C14H14N4O4
-
Color White to off-white
-
SMILES
O=C1NOCC1/N=C/C2=CC=C(/C=N/C3C(NOC3)=O)C=C2
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Lösungsmittel & Löslichkeit
In Vitro:
0.5 M NaOH : 25 mg/mL (82.70 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Reinheit & Dokumentation
-
Data Sheet (271 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| 0.5 M NaOH | 1 mM | 3.3081 mL | 16.5404 mL | 33.0808 mL | 82.7020 mL |
| 5 mM | 0.6616 mL | 3.3081 mL | 6.6162 mL | 16.5404 mL | |
| 10 mM | 0.3308 mL | 1.6540 mL | 3.3081 mL | 8.2702 mL | |
| 15 mM | 0.2205 mL | 1.1027 mL | 2.2054 mL | 5.5135 mL | |
| 20 mM | 0.1654 mL | 0.8270 mL | 1.6540 mL | 4.1351 mL | |
| 25 mM | 0.1323 mL | 0.6616 mL | 1.3232 mL | 3.3081 mL | |
| 30 mM | 0.1103 mL | 0.5513 mL | 1.1027 mL | 2.7567 mL | |
| 40 mM | 0.0827 mL | 0.4135 mL | 0.8270 mL | 2.0676 mL | |
| 50 mM | 0.0662 mL | 0.3308 mL | 0.6616 mL | 1.6540 mL | |
| 60 mM | 0.0551 mL | 0.2757 mL | 0.5513 mL | 1.3784 mL | |
| 80 mM | 0.0414 mL | 0.2068 mL | 0.4135 mL | 1.0338 mL |
Terizidone Related Classifications
HY-112324 Related Classifications
Powered by Bioz